Figure 9.

The anti-tumor effect of TQ is proved in animal model of bladder carcinoma, which was established by injection of T24 cells subcutaneously or through the tail veins. (A) Gross samples of bladder tumors with different treatment. (B, C) Subcutaneous tumors were weighed and the volume changes of tumors were recorded and calculated. (D) Body weight measurement presented no significant variations between three groups. (E) qRT-PCR experiment was conducted to test the level of hsa-miR-877-5p in tumor tissues. (F) WB experiment was used to detect the alterations of N-cad, MMP2, PD-L1, cleaved PARP, p62 and LC3B proteins in tumor tissues. (G) For nude mice treated with NS and TQ administration, immunochemistry experiment was also performed to test the variations of different proteins in xenograft tumors, including cleaved PARP, LC3B, MMP2, PD-L1, E-cad and N-cad. (H) H&E staining was used to test the organ related toxicity in groups of NS and TQ administration. (I) The metastatic nodules in mice lungs with NS and TQ administration were observed and counted by H&E staining. NS: normal saline; DDP: cisplatin; WB western blot; *p<0.05, **p<0.01.